{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:18:45Z","timestamp":1791580725977,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFE0206600"],"award-info":[{"award-number":["2021YFE0206600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"publisher","award":["MYRG2022-00203-ICMS"],"award-info":[{"award-number":["MYRG2022-00203-ICMS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"publisher","award":["MYRG-GRG2023-00134-ICMS-UMDF"],"award-info":[{"award-number":["MYRG-GRG2023-00134-ICMS-UMDF"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0096\/2020\/AMJ"],"award-info":[{"award-number":["0096\/2020\/AMJ"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.actbio.2024.12.022","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T01:34:10Z","timestamp":1733621650000},"page":"340-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Fluorinated polyethyleneimine vectors with serum resistance and adjuvant effect to deliver LMP2 mRNA vaccine for nasopharyngeal carcinoma therapy"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9898-1369","authenticated-orcid":false,"given":"Suleixin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiwan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2024.12.022_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1079515","article-title":"Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma","volume":"13","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2024.12.022_bib0002","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ejca.2007.03.022","article-title":"Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial","volume":"43","author":"Chitapanarux","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.actbio.2024.12.022_bib0003","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.actbio.2024.12.022_bib0004","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1002\/ijc.32869","article-title":"Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: beyond an era of chemoradiation?","volume":"146","author":"Masterson","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.actbio.2024.12.022_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221096214","article-title":"Current status and advances of immunotherapy in nasopharyngeal carcinoma","volume":"14","author":"Xu","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.actbio.2024.12.022_bib0006","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein\u2013Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2024.12.022_bib0007","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.7150\/jca.37282","article-title":"Epstein barr virus associated lymphomas and epithelia cancers in humans","volume":"11","author":"Ayee","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.actbio.2024.12.022_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.629780","article-title":"The impact of epstein-barr virus infection on epigenetic regulation of host cell gene expression in epithelial and lymphocytic malignancies","volume":"11","author":"Leong","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.actbio.2024.12.022_bib0009","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/v15030714","article-title":"Epstein\u2013barr virus history and pathogenesis","volume":"15","author":"Yu","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.actbio.2024.12.022_bib0010","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/s41388-020-01631-2","article-title":"The molecular march of primary and recurrent nasopharyngeal carcinoma","volume":"40","author":"Campion","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.actbio.2024.12.022_bib0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1051\/vcm\/2021003","article-title":"Metastasis of nasopharyngeal carcinoma: what we know and do not know","volume":"2","author":"Guo","year":"2021","journal-title":"Vis. Cancer Med"},{"key":"10.1016\/j.actbio.2024.12.022_bib0012","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2018.00265","article-title":"Epstein\u2013Barr virus-associated malignancies: roles of viral oncoproteins in carcinogenesis","volume":"8","author":"El-Sharkawy","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.actbio.2024.12.022_bib0013","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding epstein\u2013barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.actbio.2024.12.022_bib0014","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-\u0394LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma","volume":"23","author":"Chia","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.actbio.2024.12.022_bib0015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/cmi.2015.29","article-title":"Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein\u2013Barr virus as a potential vaccine and diagnostic agent","volume":"13","author":"Lin","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.actbio.2024.12.022_bib0016","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1248\/cpb.c16-00114","article-title":"The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a phase I clinical trial and two-year follow-up","volume":"64","author":"Si","year":"2016","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.actbio.2024.12.022_bib0017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2024.12.022_bib0018","first-page":"1","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.actbio.2024.12.022_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20210146","article-title":"From structural design to delivery: mRNA therapeutics for cancer immunotherapy","volume":"4","author":"Zhou","year":"2024","journal-title":"Exploration"},{"key":"10.1016\/j.actbio.2024.12.022_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120431","article-title":"Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice","volume":"266","author":"Islam","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2024.12.022_bib0021","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and mRNA vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.actbio.2024.12.022_bib0022","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1007\/s12274-022-5254-x","article-title":"A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma","author":"Guo","year":"2023","journal-title":"Nano Res"},{"key":"10.1016\/j.actbio.2024.12.022_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2024.12.022_bib0024","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2024.12.022_bib0025","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1021\/acs.jpclett.1c03898","article-title":"Opportunities and challenges for mRNA delivery nanoplatforms","volume":"13","author":"Zhang","year":"2022","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.actbio.2024.12.022_bib0026","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","article-title":"A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine","volume":"92","author":"Boussif","year":"1995","journal-title":"Proc. Natl. Acad. Sci"},{"key":"10.1016\/j.actbio.2024.12.022_bib0027","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41565-020-00781-4","article-title":"A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy","volume":"15","author":"Xu","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2024.12.022_bib0028","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.actbio.2017.10.019","article-title":"Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses","volume":"64","author":"Li","year":"2017","journal-title":"Acta Biomater"},{"key":"10.1016\/j.actbio.2024.12.022_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2022.140930","article-title":"Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines","volume":"456","author":"Li","year":"2023","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.actbio.2024.12.022_bib0030","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1039\/D0CS00258E","article-title":"Fluoropolymers in biomedical applications: state-of-the-art and future perspectives","volume":"50","author":"Lv","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.actbio.2024.12.022_bib0031","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1021\/acs.nanolett.6b02536","article-title":"Ultrasensitive pH Triggered Charge\/Size dual-rebound gene delivery system","volume":"16","author":"Guan","year":"2016","journal-title":"Nano Lett"},{"key":"10.1016\/j.actbio.2024.12.022_bib0032","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.actbio.2021.11.042","article-title":"ROS-responsive fluorinated polyethyleneimine vector to co-deliver shMTHFD2 and shGPX4 plasmids induces ferroptosis and apoptosis for cancer therapy","volume":"140","author":"Yang","year":"2022","journal-title":"Acta Biomater"},{"key":"10.1016\/j.actbio.2024.12.022_bib0033","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acs.accounts.1c00766","article-title":"Fluorination promotes the cytosolic delivery of genes, proteins, and peptides","volume":"55","author":"Lv","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.actbio.2024.12.022_bib0034","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.drudis.2013.06.014","article-title":"Polymer gene delivery: overcoming the obstacles","volume":"18","author":"Aied","year":"2013","journal-title":"Drug Discov. Today"}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124007323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124007323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:25:36Z","timestamp":1778624736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706124007323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"alternative-id":["S1742706124007323"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2024.12.022","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluorinated polyethyleneimine vectors with serum resistance and adjuvant effect to deliver LMP2 mRNA vaccine for nasopharyngeal carcinoma therapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2024.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}